🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

21 results for “Protalix” Clear

  1. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  2. PRX-102

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 small molecule completed

    2 trials

  3. PRX-102 (pegunigalsidase alfa)

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    3 trials

  4. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial

  5. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  6. Ibuprofen-PC

    Protalix BioTherapeutics

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  7. Naproxen

    Protalix BioTherapeutics

    Healthy Volunteers

    phase 2 small molecule completed

    1 trial

  8. OPRX-106

    Protalix BioTherapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. PL2200

    Protalix BioTherapeutics

    Gastroduodenal Ulceration

    phase 2 small molecule completed

    1 trial

  10. PL3100

    Protalix BioTherapeutics

    Gastroduodenal Ulcerations

    phase 2 small molecule completed

    1 trial

  11. PRX-112

    Protalix BioTherapeutics

    Gaucher Disease

    phase 2 small molecule completed

    2 trials

  12. PRX-115

    Protalix BioTherapeutics

    Gout

    phase 2 mab active

    2 trials

  13. acetylsalicylic acid

    Protalix BioTherapeutics

    Upper Gastrointestinal Mucosal Damage

    phase 2 small molecule completed

    1 trial

  14. AIR DNase

    Protalix BioTherapeutics

    Cystic Fibrosis (CF)

    phase 1 small molecule completed

    1 trial

  15. Aspirin

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  16. Human Glucocerebrosidase (prGCD)

    Protalix BioTherapeutics

    Gaucher Disease

    phase 1 small molecule completed

    1 trial

  17. OPRX-106

    Protalix BioTherapeutics

    Human Volunteer

    phase 1 small molecule completed

    1 trial

  18. PL2200 fasted

    Protalix BioTherapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  19. PRX-105

    Protalix BioTherapeutics

    Organophosphate Exposure

    phase 1 small molecule completed

    1 trial

  20. Pharmaceutical-lipid aspirin (PL-ASA)

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  21. PL-ASA

    Protalix BioTherapeutics

    Healthy Volunteers

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources